Insights from Brain’s Waste-Flushing System May Improve Diagnosis of Idiopathic Intracranial Hypertension
MRI analysis that measures the activity of the glymphatic system may offer a noninvasive method for diagnosing unexplained brain pressure.
Press Release5 Minute ReadAug | 19 | 2021
Mohammad S. Jalali, PhD, MScLagged reporting has clouded the understanding of the effects of the COVID-19 pandemic on opioid-related overdose deaths. Our work represents the first multi-state report with detailed analyses.
BOSTON – The COVID-19 pandemic has disrupted the social support and economic stability of many individuals, which experts have warned could lead to a rise in opioid overdoses and opioid-related deaths. In a recent study shared on medRxiv, researchers at Massachusetts General Hospital (MGH) and Harvard Medical School characterized how the nature of such deaths have changed in nine9 U.S. states since the onset of the pandemic.
The study examined trends in opioid overdose deaths in Alaska, Colorado, Connecticut, Indiana, Massachusetts, North Carolina, Rhode Island, Utah and Wyoming during the COVID-19 pandemic as compared with 2018 and 2019.
The analysis revealed various trends that arose during the pandemic:
“Drug overdose data are collected and reported more slowly than COVID-19 data, from about 4 to 8 months’ lag in Massachusetts and North Carolina to over one year in Maryland and Ohio,” says senior author Mohammad S. Jalali, PhD, MSc, a senior scientist at MGH’s Institute for Technology Assessment and an assistant professor at Harvard Medical School. “This lagged reporting has clouded the understanding of the effects of the COVID-19 pandemic on opioid-related overdose deaths. Our work represents the first multi-state report with detailed analyses.”
The results may be useful for identifying and treating at-risk individuals. “Practitioners and policy makers can use our findings to help them anticipate which groups of people might be most affected by opioid overdose and which types of policy interventions might be most effective given each state’s unique situation,” says lead author Gian-Gabriel P. Garcia, PhD, who was a postdoctoral fellow at MGH and Harvard Medical School during the study and is currently an assistant professor at Georgia Tech.
Co-authors of the study include Erin J. Stringfellow, PhD, MSW, Catherine DiGennaro, BA1, Nicole Poellinger, MPH, Jaden Wood, BA, and Sarah Wakeman, MD.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2021, Mass General was named #5 in the U.S. News & World Report list of "America’s Best Hospitals."
MRI analysis that measures the activity of the glymphatic system may offer a noninvasive method for diagnosing unexplained brain pressure.
A new clinical trial by investigators from Mass General Brigham found that the wake-promoting drug solriamfetol (Sunosi) helped early morning shift workers with shift work disorder stay more alert.
A national clinical trial led by investigators at Mass General Brigham Cancer Institute has found that abemaciclib, an oral cancer drug, may slow tumor growth in patients with aggressive meningiomas that have specific genetic mutations.
Mass General Brigham-developed system achieved high accuracy in validation studies, prompting release on open source to enable further investigations.
A team led by investigators at the Mass General Brigham Cancer Institute has discovered that a particular marker on tumor cells circulating in the blood indicates whether a patient with lung cancer will experience a lasting response to a newly approved immunotherapy called tarlatamab.
A new study by Mass General Brigham investigators identifies mutations that drive clinical resistance to rezatapopt treatment.
